USFDA completes inspection of NATCO’s Chennai formulation facility

Published: 15.07.2019 13:28
USFDA completes inspection of NATCO’s Chennai formulation facility
Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) is pleased to announce successful completion of regulatory inspection from the U.S. Food and Drug
Administration (FDA) for its Active Pharmaceutical Ingredient (API) facility in Chennai, India, conducted during the period July 8th – 12th, 2019. The regulatory
audit resulted in zero observations.

 


Copyright © 2007-2018 by PSS Pharmaceuticals International All Rights Reserved.